Background
Lung adenocarcinoma (LUAD) is the most commonly occurring histological type of lung cancer, which often has major driver oncogenes such as EGFR mutation 1 and ALK fusion. 2 Previous studies have shown that the genomic alterations in LUAD are different from those in other lung cancer subtypes. 3, 4 The current prediction systems for non-small-cell lung cancer (NSCLC) such as tumor, node, and metastases (TNM) staging 5 and microarray-data-based prognostic modeling 6 have not effectively distinguished lung cancer subtypes in terms of NSCLC patient survival. Moreover, the prognoses within the same TNM stage vary widely 7 and the gene signature is yet limited in coding genes 8 and microRNAs. 6, 9 Evidence provides the primary rationale to develop the lncRNA model for predicting lung cancer survival.
lncRNAs are a class of RNA molecules with more than 200 nucleotides in length and have no evident open reading frames. 10 These long molecules play key roles in gene regulation and carcinogenesis including proliferation, adhesion, migration and apoptosis. 11 Current non-coding RNA profiling research reveals that lncRNAs are dysregulated among cancers 12 and some may serve as promising therapeutic
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shi et al targets. 13 For instance, Gutschner et al reported that elevated MALAT1 expression was associated with metastasis in multiple tumor types. 14 Previous meta-analysis showed that MALAT1 may have a role in cancer prognosis. 15 It is believed that the clinical value of lncRNA is not confined to candidate biomarkers for diagnostic and prognostic purposes. Also, lncRNA expression profiling by RNA sequencing (RNA-seq) might be useful in the classification of various cancers such as lung cancer; it is important for prognostic determinations as well. 12 A large number of lncRNAs have been investigated in cancer research. 11, 16 Some of these lncRNAs are associated with patient survival, 17 ,18 but most of the reports are only supported by clinical survival data from samples within a single institute 19 or pooled clinical data with some heterogeneities. 20 Given the heterogeneity of LUAD and the susceptibility of non-coding RNA decay, a panel of the lncRNA biomarkers should be more precisely stable for LUAD prognosis determinations. However, using only a single lncRNA would yield unreliable results in predicting cancer survivals. Previous studies have also observed that gene signatures and clinical characteristics among patients are associated with overall survival (OS) 21, 22 aiming to overcome the limitations of the current TNM staging for predicting clinical outcomes. Several studies have reported that lncRNA expression profiles can be obtained from publicly available microarray data to perform analysis for the development of cancer survival models. 23 , 24 However, RNA-seq-based prognostic lncRNA expression signature for the prediction of LUAD patient survival has not yet been investigated. Though a number of prognostic lncRNA biomarkers for NSCLC have been proposed, 25-27 none of them have been successfully applied in real clinics. This is partially due to differences in the acquisition of samples and the usage of different systems for detection. In addition, the populations selected for lncRNA studies of cancer may vary and display inconsistencies. Moreover, the potential role of lncRNA as biomarkers for diagnosis and prognosis is better understood by the patterns of the lncRNA expression profile in the genome rather than as a single lncRNA expression abnormality. Notably, as we mentioned previously, the genomic characteristics of LUAD and squamous cancer distinguish greatly, 4 and previous studies identifying the signature pattern of NSCLC may be modified further by separate analysis of each cancer subtype.
To construct a reliable prognostic lncRNA signature that could improve the current staging system for predicting LUAD survival, we identified lncRNAs that can stratify the risk of LUAD recurrence through survival outcomes. RNA-seq data and corresponding clinical data were analyzed to identify lncRNAs that associate with the risk of LUAD recurrence in patients. A panel of key lncRNAs was identified by next generation sequencing technology, which could diagnose one of the major histological subtypes of lung cancer with fairly high specificity and sensitivity. We developed a risk score formula for predicting the OS time of LUAD patients. In summary, the use of the lncRNA signature provided a deeper insight into the parameters associated with LUAD than what is used exclusively for LUAD prognosis.
Materials and methods lung adenocarcinoma Rna-seq data from TCga
Level 3 RNA-seq data (HTSeq-FPKM-UQ) and the corresponding clinical data of 519 LUAD patients were obtained from the public The Cancer Genome Atlas data portal website (http://cancergenome.nih.gov). Clinicopathological parameters including age, gender, smoking history and TNM stage were also assessed. Patients with incomplete clinical data or OS of less than 1 month were excluded from the analysis. No correlations between patients' gender as well as expression profile and OS were found; after data filtering and exclusions, a total of 462 LUAD samples comprising 250 females and 212 males were enrolled in the model.
Identification of differentially expressed lncRnas in lUaD and normal lung tissue samples
To identify lncRNAs that are differentially expressed between LUAD and normal lung tissues, the raw counts of TCGA RNA-seq data (HTSeq-Counts) were downloaded for the analysis. Differential expression analysis was performed using the DESeq package in Bioconductor. 28 The thresholds for screening the expression differences of lncRNAs were adjusted p-value <0.01 and |log 2 (fold change)|>2. The log 2 (fold change) indicates the fold change in the expression of each lncRNA between LUAD and normal lung tissue samples.
Cox regression analysis
First, the RNA-seq expression values of differentially expressed lncRNAs were normalized with log 2 transformation. Afterward, the association between lncRNA expression and patient survival was determined by univariate Cox 
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lung adenocarcinoma lncRna survival model regression analysis. lncRNAs with a p-value less than 0.05 from the univariate Cox regression analysis were used for further mining potential lncRNAs that were associated with OS time, and they were fitted in a multivariate Cox regression analysis. The mathematical model was built based on the Akaike information criterion, which allows determination of the best trade-off between the complexity of model and its goodness of fit.
29
Risk score and survival curve Based on the multivariate Cox regression analysis, a formula (Equation 1) was built to predict the risk score for each patient. In Equation 1, G i represents expression value of the ith lncRNA and Weight i is the coefficient of each lncRNA from the Cox analysis results (Table 1 ). According to this risk scoring system, patients were divided into low-risk (< median risk score) and high-risk (> median risk score) groups. Subsequently, the log-rank statistical test was used to determine the differences in survivals between the lowrisk and high-risk groups. A Kaplan-Meier OS curve was plotted against the two groups and the hazard ratio was calculated. Cox multivariate analysis was employed to test whether the risk score was independent of potential clinical risk factors including age, gender, smoking history and disease stage. The prognostic performance was measured by calculating the area under the receiver operating characteristic curve. 
Results
Differentially expressed lncRnas in lUaD patients
The analysis of the lncRNA expression profiles in both LUAD tissues and normal lung tissues identified a total of 346 differentially expressed lncRNAs, which were used for subsequent survival analyses (Table S1 ). Compared to normal samples, 249 lncRNAs were overexpressed and 97 lncRNAs were underexpressed in LUAD samples. A cluster dendrogram was generated to ensure that the differentially expressed lncRNAs were good characterizations of LUAD ( Figure S1 ).
The association of lncRna expressions and Os time
To identify the lncRNAs associated with patient survival in LUAD, univariate Cox regression analysis for the differentially expressed lncRNAs data was assessed. With the significance level threshold of 0.05, a set of 60 lncRNAs was selected (Table S2 ). These lncRNAs were used in stepwise multivariate Cox regression analysis and 31 lncRNAs were chosen. A cluster dendrogram for these 31 lncRNAs is shown in Figure 1 . We conducted a risk score analysis using Equation 1 on the 31 lncRNAs to calculate risk scores for patients. The coefficients of the 31-lncRNA model for determining risk scores are listed in Table 1 .
Stage prognostic classifiers
Tumor stage classification was significantly associated with OS of LUAD patients. In order to test whether the 31-lncRNA model is applicable for the prediction of LUAD survival in all stages, we calculated the risk scores for patients in all stages and divided the patients into high-risk and low-risk groups according to the median risk score of patients in all stages (value=1.111). Kaplan-Meier survival curves are displayed in Figure 2 , showing that the 31-lncRNA model performs well for LUAD in all stages (p-value=8.508e-11).
survival times of low-risk and high-risk groups in stage i
Since tumor stage serves as an important factor that independently affects the survival of LUAD patients, we applied the 31-lncRNA model to stage I patients in order to test the effectiveness of the survival prediction. We divided the patients into high-risk and low-risk groups using the median risk score value 1.111, and found that the high-risk group correlated with poor prognoses for OS (log-rank test p-value 8.917e-13 
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lung adenocarcinoma lncRna survival model 89.5% (95% CI: 80.7%-99.2%) for the high-risk and lowrisk groups, respectively. The Kaplan-Meier OS curves as well as ROC curves (Figure 3 ) indicated that the AUC of the 31-lncRNA model was 0.881 (Figure 4 ), which demonstrated that the 31-lncRNA model has high specificity and sensitivity in predicting the OS time of LUAD patients.
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Discussion
In present study, lncRNA expression data and clinical data were obtained from the public TCGA database (HTSeq-FPKM-UQ) of LUAD level 3 RNA-seq. A total of 254 stage I LUAD patients were included. lncRNAs associated with survival were identified by stepwise multivariate Cox regression analysis. Subsequently, an expression pattern of 31 lncRNAs was found to be significantly associated with OS of LUAD patients. The 31-lncRNA panel accurately predicted OS and was applied to conduct a risk score analysis for further investigation of the specificity and sensitivity. ROC analysis results indicate that the statistical power of 31-lncRNA model for high-risk and low-risk patients is formidable. Therefore, the 31-lncRNA signature predicts OS fairly well based on TCGA data sets, which shows its good predictive performance. The AUC was 0.881, which is better than previously reported results.
Some of the lncRNAs that are predicted in our analysis were shown previously to function as potential biomarkers. LINC00473 has been found to correlate with poor NSCLC prognosis. 25 Its overexpression is required for the growth and survival of LKB1-inactivated NSCLC cells through CREBregulated transcription coactivator/CREB-mediated transcription. 25 In addition, four lncRNAs including RP11-434D9.1 were found to be differentially expressed in microarray analyses.
30 RP11-434D9.1 is correlated with TNBC occurrence, and is a potential biomarker for diagnosis for breast cancer treatment. 30 Notably, one lncRNA, CCAT1, was reported to be associated with a variety of solid tumors. Abnormal expression of CCAT1 has been shown in a variety of tumors including Figure 2 survival curves for lUaD patients in all stages using 31-lncRna model. The differences between the high-risk (n=222) and low-risk (n=240) groups were determined by the log-rank test. Abbreviation: lUaD, lung adenocarcinoma. The differences between the high-risk (n=126) and low-risk (n=126) groups were determined by the log-rank test. Abbreviation: lUaD, lung adenocarcinoma. Cancer Management and 39 Currently, some evidences show that CCAT1 acts as a driver lncRNA of malignancy through miRNA sponging. CCAT1 also functions as a molecular sponge for let-7c in docetaxel-resistant LUAD cells, 33 and miR-155 in acute myeloid leukemia HL-60 cells. Therefore, CCAT1 may hold an important role in the carcinogenesis of LUAD. Our lncRNA model includes cancerassociated lncRNAs that provide reference values for investigators and give eventuality of explorations in this perspective.
The risk score of the 31-lncRNA signature model was found to have an independent correlation with OS (p-value <0.001) ( Table 1) . Moreover, we found that one of the clinicopathological parameters of LUAD in the TCGA data, i.e., tumor staging, was significantly associated with OS, 5 which was consistent in clinical practice. Furthermore, tumor staging does not efficiently stratify the risk of early stage (stage I and II) LUAD patients. Since this parameter may affect the predictive performance of the model for cancer survival, we further tested the model in stage I LUAD patients. We calculated the risk score for each early stage patient, and the results indicate that the 31-lncRNA signature model is potentially a prognostic classifier for early stage LUAD patients (p-value <0.001). This suggests that patients in stage I and II could be divided into high-risk and low-risk groups by their lncRNA signatures. The results imply that patients with LUAD may benefit from this prognostic signature model, which could determine timeline of adjuvant chemotherapy treatments. There is a speculation that further treatments such as adjuvant therapy will alter the effectiveness of the predictions; however, relevant modifications could be adapted accordingly under the proposed framework.
Using the updated TCGA data (June 2016 version), we were able to obtain 60,483 data points including both protein coding and non-coding genes. Many of these genes are known biomarkers and some are novel genes with survival records. This broadens our scope in gene signature modeling for cancer survival prediction. The prognostic power of the signature model in this study is applied for predicting OS of stage I patients. Moreover, since these lncRNAs might have a predicative role in the outcome of LUAD, further experimental studies to survey the biological roles of these lncRNAs in carcinogenesis are worthwhile to shed new light on specific investigations. Present results show that the current prognostic model is promising and further validations on independent datasets are still needed. In addition, coregulatory relationship between these 31 lncRNAs will affect the model efficacy, which would be validated furthermore.
Based on this work, further analysis such as expression network and co-expression analysis could be applied.
This model is not without limitations. First of all, the data that we could access and analyze are still limited. The TCGA data involved fresh frozen samples, which were collected from top-notch institutions with robust tissue collection systems in place. Thus, only samples that were found to be of very high quality were included. Data in an average setting are expected to be applied by the model to further verify its robustness. For instance, further available data could be applied to analyze the correlation between the lncRNA profile and etiology such as smoking by patients or air pollutant profile of the local area of Guangzhou as well as the expression pattern. With more relevant data, a complete co-expression network could be derived.
Conclusion
In this study, we developed a signature model ( Table 1) that is associated with OS in LUAD patients. Patients with a highrisk score from the model have shorter survival time, and this lncRNA panel could help to serve as a prognostic classifier for LUAD. The results of this study suggest that these lncRNAs may play specific roles in the carcinogenesis of LUAD and be of potential prognostic values. Further experiments are needed to verify the connection of 31 lncRNAs to cell survival and apoptosis linking with DNA repair. This model is LUAD specific, and proper adjustments could be made for reference of other disease-associated models.
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